Locations:
Search
Initial study results are encouraging
Higher doses don’t mean higher toxicity
New system better predicts patient outcomes
May help identify patients for immunotherapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Second (or third) time’s a charm in reducing splenomegaly and other symptoms
Using data science to identify intrinsic patterns in cancer data
Fat necrosis is a benign but real concern
Consortium aims to reduce life-threatening side effect of therapy
Predicts drug response in patient with rare, aggressive cancer
Outcomes hold promise for future RCT results
Advertisement
Advertisement